Pegaptanib for choroidal neovascularization in treatment-naïve exudative age-related macular degeneration

Ophthalmic Surgery Lasers and Imaging

Volumn 38, Issue 5, 2007, Pages 371-377

  Ehlers, Justis P ^b   Fintak, David R ^b   Gupta, Omesh P ^b   Regillo, Carl D ^a   Fineman, Mitchell S ^a   Ho, Allen C ^a,b  

^a Retina Service   (United States)

^b WILLS EYE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGAPTANIB;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; RETINA MACULA HEMORRHAGE; RETINAL PIGMENT EPITHELIUM RIP; RETROSPECTIVE STUDY; RISK; SUBRETINAL HEMORRHAGE; SUBRETINAL NEOVASCULARIZATION; TRANSIENT ISCHEMIC ATTACK; VISUAL ACUITY; VISUAL IMPAIRMENT; VITREOUS HEMORRHAGE;

EID: 35848959519     PISSN: 15428877     EISSN: None     Source Type: Journal    
DOI: 10.3928/15428877-20070901-03     Document Type: Article

References (9)

1. Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol. 2005;40:352-368.
2. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351: 2805-2816.
3. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology. 2006;113:e1-e12.
4. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina. 2006;26:495-511.
5. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-1431.
6. Gonzales CR, VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. Retina. 2005;25:815-827.
7. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, D'Amico DJ, Masonson HN, et al. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology. 2006;113:992-1001.
8. Dhalla MS, Blinder KJ, Tewari A, Hariprasad SM, Apre RS. Retinal pigment epithelial tear following intravitreal pegaptanib sodium. Am J Ophthalmol. 2006;141:752-754.
9. Singh RP, Sears JE. Retinal pigment epithelial tears after pegaptanib injection for exudative age-related macular degeneration. Am J Ophthalmol. 2006;142:160-162.